10-K: Palvella Therapeutics Reports Positive Phase 3 Results, Secures Funding

Palvella Therapeutics announced positive Phase 3 clinical trial results for QTORIN rapamycin in microcystic lymphatic malformations and secured $215.8 million in a public offering, despite ongoing operating losses.

Summary

• Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious, rare skin diseases and vascular malformations using its QTORIN platform.
• The company reported positive topline results in February 2026 from its Phase 3 SELVA study of QTORIN rapamycin for microcystic lymphatic malformations (microcystic LMs), meeting the primary endpoint with a +2.13 improvement on the mLM-IGA scale (p<0.001).
• In the SELVA study, 95% of participants aged 6 and older showed at least a 1-point improvement, and 86% were rated 'Much Improved' or 'Very Much Improved'.
• QTORIN rapamycin for microcystic LMs has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug Designations, as well as European Commission orphan medicinal product designation.
• The company plans to submit a pre-NDA meeting request to the FDA in Q1 2026, with the meeting anticipated in Q2 2026, and aims for a rolling NDA submission in H2 2026.
• Positive topline efficacy results were announced in December 2025 from the Phase 2 TOIVA study of QTORIN rapamycin for cutaneous venous malformations (cutaneous VMs), showing nominally statistically significant improvements (p<0.001) on multiple endpoints.
• In the TOIVA study, 73% of participants improved on the Overall cVM-IGA, with 67% rated 'Much Improved' or 'Very Much Improved'.
• QTORIN rapamycin for cutaneous VMs has received FDA Fast Track Designation, and the company intends to submit an application for Breakthrough Therapy Designation in Q2 2026.
• Palvella expanded its QTORIN rapamycin development program into clinically significant angiokeratomas in September 2025, receiving FDA Fast Track Designation and written feedback on a proposed Phase 2 study.
• A new product candidate, QTORIN pitavastatin, was announced in November 2025 for disseminated superficial actinic porokeratosis (DSAP), with a Phase 2 study anticipated in H2 2026.
• The company completed a reverse merger with Legacy Palvella on December 13, 2024, and concurrently closed a PIPE financing, raising approximately $78.9 million ($60.0 million in cash).
• In February 2026, Palvella completed a public offering of common stock, generating net proceeds of approximately $215.8 million.
• As of December 31, 2025, the company reported a net loss of $41.7 million and an accumulated deficit of $135.5 million.
• Research and development expenses increased to $22.8 million in 2025 from $8.2 million in 2024, primarily due to increased clinical development activities.
• General and administrative expenses increased to $15.8 million in 2025 from $5.9 million in 2024, driven by increased headcount and public company operating costs.
• The company has a Development Funding and Royalties Agreement with Ligand Pharmaceuticals, Inc., under which Ligand provided $15.0 million in funding and is entitled to up to $8.0 million in milestone payments ($5.0 million remaining) and tiered royalties of 8.0% to 9.8% on net product sales of QTORIN rapamycin.
• Palvella's intellectual property portfolio includes patents for anhydrous gel formulations of rapamycin expiring in 2038, and pending applications for specific uses extending to 2042 and 2046.
• The company had 29 full-time employees as of March 25, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong clinical trial results for its lead candidate in multiple rare disease indications, coupled with significant regulatory designations and a successful capital raise that substantially improves its financial runway. While operating losses persist, the clinical progress and funding mitigate immediate concerns.

Positives

• QTORIN rapamycin achieved positive topline results in its Phase 3 SELVA study for microcystic LMs, meeting the primary endpoint with a statistically significant improvement of +2.13 points (p<0.001).
• The Phase 3 SELVA study demonstrated high response rates, with 95% of participants (aged 6+) showing at least a 1-point improvement and 86% being 'Much Improved' or 'Very Much Improved'.
• QTORIN rapamycin was well-tolerated in the Phase 3 SELVA study, with all treatment-related adverse events rated mild or moderate and systemic rapamycin levels remaining low (<2 ng/mL).
• QTORIN rapamycin for microcystic LMs holds multiple key FDA designations: Breakthrough Therapy, Fast Track, and Orphan Drug Designation, which can expedite development and review.
• The company received an FDA Orphan Products Clinical Trials Grant of up to $2.6 million to support the SELVA Phase 3 study, with $1.1 million received to date.
• QTORIN rapamycin showed positive topline efficacy results in its Phase 2 TOIVA study for cutaneous VMs, achieving nominal statistical significance (p<0.001) on multiple clinicianand patient-reported endpoints.
• The Phase 2 TOIVA study for cutaneous VMs indicated significant improvement, with 73% of participants improving on the Overall cVM-IGA and 67% being 'Much Improved' or 'Very Much Improved'.
• QTORIN rapamycin for cutaneous VMs has received FDA Fast Track Designation.
• The company expanded its QTORIN rapamycin program into clinically significant angiokeratomas, an indication with no FDA-approved therapies, and received FDA Fast Track Designation.
• Introduction of QTORIN pitavastatin for disseminated superficial actinic porokeratosis (DSAP) represents pipeline expansion into another rare skin disease with no approved therapies.
• The QTORIN platform is versatile and reproducible, designed to deliver high payloads of API to deep skin layers with minimal systemic absorption, potentially reducing systemic side effects.
• The company successfully completed a public offering in February 2026, raising approximately $215.8 million in net proceeds, significantly bolstering its cash position.
• Palvella's intellectual property portfolio includes issued patents for QTORIN rapamycin formulations expiring in 2038 and pending applications for specific uses extending to 2042 and 2046, providing long-term protection.

Negatives

• The company incurred significant operating losses of $38.6 million in 2025, an increase from $14.1 million in 2024, and has an accumulated deficit of $135.5 million as of December 31, 2025.
• Palvella has never generated revenue from product sales and anticipates continued significant operating losses for at least the next several years, with no assurance of achieving or maintaining profitability.
• The effective interest rate on the Ligand royalty agreement liability is very high at 44.9% as of December 31, 2025, indicating a substantial cost of capital for this funding arrangement.
• The FDA has commented that a placebo-controlled trial or additional trials assessing different clinical endpoints may be required to assess the efficacy of QTORIN rapamycin for microcystic LMs, potentially delaying approval or increasing costs.
• The company's development and commercialization strategy relies on the novel and unproven QTORIN platform, and negative results in any QTORIN-based program could decrease confidence in the technology.
• There is a risk of difficulty enrolling sufficient subjects in clinical trials due to the small patient populations of the rare diseases targeted, which could delay or terminate trials.
• The company relies on a limited number of contract manufacturing organizations (CMOs) and sole-source suppliers, posing risks of supply disruption, quality issues, or increased costs.
• Competition from compounding pharmacies offering topical rapamycin or pitavastatin formulations could reduce the market potential for Palvella's approved products.
• The company's ability to utilize its net operating loss (NOL) carryforwards may be limited by Section 382 of the Code due to past ownership changes, potentially increasing future tax liabilities.
• The company will need to build an independent commercial organization, which involves significant expenses and risks, or rely on third-party collaborators, potentially reducing profitability.
• Unfavorable global economic or political conditions, including inflation, geopolitical tensions, and healthcare reform measures (e.g., IRA, OBBBA), could adversely affect the business, pricing, and reimbursement.

Risks

• Historically incurred significant operating losses and anticipates continued losses for several years, may never achieve or maintain profitability.
• Requires substantial additional funding to finance operations, which may cause dilution to stockholders or force delays/termination of product development.
• Future success is substantially dependent on the successful clinical development, regulatory approval, and commercialization of QTORIN rapamycin.
• May be unable to obtain regulatory approval for product candidates under applicable regulatory requirements, impacting revenue generation.
• Rare skin diseases and vascular malformations targeted have no FDA-approved therapies, leading to complexities and risks in clinical development programs, including novel/subjective clinical endpoints and varying patient populations.
• Lead product candidates are based on the QTORIN platform, a novel and unproven technology, making the company highly dependent on its successful development.
• Orphan Drug Designation may not be obtained for other product candidates or the benefits (e.g., marketing exclusivity) may not be realized.
• Development and commercialization strategy relies on published scientific literature and FDA's prior findings (505(b)(2) pathway); if this strategy is not viable, regulatory approval may be delayed.
• Breakthrough Therapy Designation may not lead to faster development, regulatory review, or approval, or increase the likelihood of marketing approval.
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, or third-party payors.
• Reliance on contract manufacturing organizations (CMOs) for supplies poses risks of loss of manufacturers, failure to provide sufficient quantities, or quality/price issues.
• May not be able to obtain, maintain, or enforce patent rights of sufficient breadth to prevent third-party competition.
• Clinical drug development is lengthy, complex, expensive, and has an uncertain outcome, potentially leading to additional costs or delays.
• Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials.
• May find it difficult to enroll subjects in clinical trials, especially for rare diseases, which could cause delays.
• Other companies could receive FDA approval for topical rapamycin or pitavastatin products before Palvella, potentially gaining regulatory exclusivity and delaying Palvella's market entry.
• Serious adverse or unacceptable side effects may be identified during development, preventing or delaying regulatory approval and commercialization.
• Interim, topline, or preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• May expend limited resources on a particular product candidate or indication and fail to capitalize on more profitable opportunities.
• May choose not to continue developing or commercializing product candidates at any time, reducing return on investment.
• If commercializing outside the U.S., will face risks associated with international operations, including different regulatory requirements, price controls, and enforcement challenges.
• Estimated market opportunities for product candidates are subject to uncertainties and may prove inaccurate.
• Inability to achieve and maintain coverage and adequate reimbursement for approved products could severely hinder commercial success.
• Substantial competition from major pharmaceutical companies, academic institutions, and compounding pharmacies.
• Subject to stringent and changing laws, regulations, and standards relating to privacy, data protection, and data security, with risks of cybersecurity incidents, data breaches, or system failures.
• Use of new and evolving technologies, such as artificial intelligence, may present cybersecurity, data privacy, intellectual property, and regulatory risks.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Extensive and ongoing regulatory obligations post-approval, with penalties for non-compliance or unanticipated problems.
• Product candidates, if approved, may cause or contribute to adverse medical events requiring reporting to the FDA, leading to sanctions if reporting fails.
• Business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws, as well as export controls and trade sanctions.
• Market price of common stock has been and is likely to continue to be volatile.
• Executive officers, directors, and principal stockholders have the ability to control or significantly influence matters submitted to stockholders.
• If equity research analysts do not publish research or reports, or publish unfavorable ones, stock price and trading volume could decline.
• Broad discretion in the use of cash and cash equivalents, which may not increase investment value.
• No anticipated cash dividends on share capital in the foreseeable future; capital appreciation is the sole source of gain.
• Provisions in charter, bylaws, and Nevada law could make it more difficult or costly for a third party to acquire the company.
• Exclusive forum provisions in articles of incorporation may limit stockholders' ability to bring claims in a preferred judicial forum.

Future Outlook

Palvella Therapeutics anticipates continued significant operating losses for the foreseeable future as it advances its product candidates through clinical trials and regulatory submissions. The company expects to incur substantial research and development expenses, particularly for late-stage clinical development and regulatory approvals of QTORIN rapamycin for microcystic LMs and cutaneous VMs, and the development of preclinical programs. If regulatory approval is obtained, significant commercialization expenses related to manufacturing, marketing, sales, and distribution are expected. The company believes its current cash and cash equivalents, augmented by the recent $215.8 million public offering, will fund operations for at least the next twelve months from the filing date, but additional capital may be required thereafter.

Management Comments

• "Our vision is to become the leading rare disease biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies."
• "We envision a future treatment paradigm in which individuals suffering from serious, rare skin diseases and vascular malformations, and the physicians treating those diseases, have significantly improved treatment options which address the underlying causes of those diseases."
• "We intend to leverage our versatile QTORIN platform to minimize the challenges and timelines typically associated with generating novel topical product candidates."
• "We believe QTORIN rapamycin, if approved, has the potential to become first line therapy and the standard of care for microcystic LMs, cutaneous VMs, or clinically significant angiokeratomas."
• "We believe the estimated TAM opportunity on an annualized basis is greater than $1 billion for microcystic LMs and greater than $1.0 billion for cutaneous VMs."
• "We believe that our existing facilities are adequate for our near-term needs but expect to need additional space as we grow."

Industry Context

StockSavvy.ai notes that Palvella Therapeutics is strategically positioning itself in the high-need, high-value rare disease market, specifically targeting rare skin diseases and vascular malformations with no FDA-approved therapies. The focus on a topical mTOR inhibitor (rapamycin) leverages a known mechanism of action while aiming to mitigate systemic toxicities, a common challenge with oral rapamycin. The multiple FDA expedited designations (Breakthrough, Fast Track, Orphan) for QTORIN rapamycin underscore the significant unmet medical need and the potential for accelerated market entry, aligning with broader industry trends favoring therapies for rare conditions. The expansion into angiokeratomas and DSAP demonstrates a pipeline-building strategy within its platform technology, a common approach for biopharmaceutical companies seeking to maximize asset value. The substantial post-period capital raise reflects investor confidence in the positive clinical data and the rare disease market's potential, despite the inherent risks of clinical development and commercialization in this specialized sector.

Comparison to Industry Standards

• Palvella's QTORIN rapamycin for microcystic LMs achieved a mean improvement of +2.13 points on the mLM-IGA in its Phase 3 SELVA study. This is a significant improvement in a disease with no FDA-approved therapies, suggesting a strong therapeutic effect compared to the current standard of care, which involves invasive procedures like surgery and sclerotherapy with high recurrence rates.
• The systemic rapamycin levels in both Phase 3 SELVA and Phase 2 TOIVA studies were consistently below 2 ng/mL, demonstrating minimal systemic absorption. This is a key differentiator compared to oral rapamycin (e.g., RAPAMUNE, approved for organ transplant rejection prophylaxis), which is associated with severe systemic toxicities like immunosuppression, peripheral edema, hypertriglyceridemia, and hypertension, making it unsuitable for chronic skin conditions.
• The company's strategy to pursue Section 505(b)(2) NDAs for QTORIN rapamycin and QTORIN pitavastatin, relying on the FDA's prior findings for approved oral rapamycin and published literature, is a common industry approach to expedite approval for new formulations or uses of existing drugs, potentially reducing the time and cost compared to a full 505(b)(1) NDA.
• Palvella's receipt of Breakthrough Therapy, Fast Track, and Orphan Drug Designations for QTORIN rapamycin for microcystic LMs aligns with industry efforts to accelerate development for serious rare diseases. For example, other rare disease companies like Sarepta Therapeutics (for Duchenne muscular dystrophy) and Vertex Pharmaceuticals (for cystic fibrosis) have leveraged similar designations to bring therapies to market faster.
• The estimated total addressable market (TAM) of over $1 billion for both microcystic LMs (>30,000 patients) and cutaneous VMs (>75,000 patients) in the U.S. positions these indications as commercially attractive within the rare disease space, comparable to other successful orphan drugs that command premium pricing due to high unmet need and limited patient populations.
• The company's reliance on contract manufacturing organizations (CMOs) is a standard practice in the biopharmaceutical industry, particularly for clinical-stage companies, to avoid the significant capital investment and operational complexities of in-house manufacturing. However, the limited number of CMOs capable of handling immunosuppressant APIs like rapamycin presents a specific challenge that requires careful management, similar to other specialized drug manufacturers.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• The PIPE financing included BVF Partners, L.P., an existing stockholder of Pieris, as one of the PIPE Investors.
• In October and December 2025, entities affiliated with BVF exercised pre-funded warrants to purchase a total of 1,071,676 shares of Common Stock.

Stakeholder Impact

• **Shareholders:** Positive clinical trial results and a significant capital raise are likely to be viewed favorably, potentially increasing share price. However, ongoing operating losses and potential future dilution from additional funding needs remain a concern. Anti-takeover provisions in corporate governance may limit opportunities for premium acquisition offers.
• **Employees:** The company's growth strategy and pipeline expansion suggest potential for increased hiring and career opportunities. Stock-based compensation plans are in place to attract and retain talent. The Insider Trading and Clawback policies ensure compliance and accountability.
• **Customers (Patients):** Successful development and commercialization of QTORIN rapamycin and QTORIN pitavastatin could provide the first FDA-approved therapies for serious, rare skin diseases and vascular malformations, addressing significant unmet medical needs and improving quality of life.
• **Suppliers/CMOs:** Continued reliance on third-party CMOs and sole-source suppliers means these partners will benefit from ongoing manufacturing contracts. However, any disruptions or failures by these suppliers could negatively impact the company's ability to bring products to market.
• **Creditors (Ligand):** Ligand Pharmaceuticals, Inc. is a significant creditor/partner, entitled to milestone payments and royalties on QTORIN rapamycin sales. The high effective interest rate on the royalty agreement liability indicates a substantial return for Ligand if the product is successful.

Next Steps

• Submit a pre-NDA meeting request to the FDA for QTORIN rapamycin for microcystic LMs in Q1 2026, with the meeting anticipated in Q2 2026.
• Plan to request FDA agreement for a rolling submission of a Section 505(b)(2) NDA for QTORIN rapamycin for microcystic LMs in H2 2026.
• Submit an application to the FDA for Breakthrough Therapy Designation for QTORIN rapamycin for cutaneous VMs in Q2 2026.
• Commence a Phase 3 pivotal study for QTORIN rapamycin for cutaneous VMs in H2 2026.
• Initiate a Phase 2 study of QTORIN rapamycin for clinically significant angiokeratomas in Q2 2026.
• Initiate a Phase 2 study of QTORIN pitavastatin for disseminated superficial actinic porokeratosis (DSAP) in H2 2026.
• Announce the fourth target clinical indication for QTORIN rapamycin in H2 2026.
• Announce the third product candidate from the QTORIN platform in H2 2026.
• File a definitive proxy statement pursuant to Regulation 14A within 120 days of December 31, 2025.

Key Dates

Recommendation

The filing presents compelling positive developments that outweigh the inherent risks of a clinical-stage biopharmaceutical company. The positive Phase 3 results for QTORIN rapamycin in microcystic LMs, coupled with Breakthrough Therapy Designation, significantly de-risk the lead asset and pave a clear path towards a potential NDA submission in H2 2026. The strong Phase 2 data for cutaneous VMs and pipeline expansion into angiokeratomas and DSAP demonstrate the versatility and potential of the QTORIN platform. Furthermore, the successful $215.8 million public offering in February 2026 provides substantial liquidity, extending the company's runway and reducing immediate funding concerns. While operating losses are expected to continue, the progress in clinical development for multiple indications with high unmet needs and large estimated market opportunities suggests significant future revenue potential. The current valuation, especially after the recent capital raise, appears to offer an attractive entry point for long-term investors willing to tolerate the risks associated with drug development.

Keywords

Rare Skin Diseases, Vascular Malformations, QTORIN Platform, Rapamycin, Sirolimus, Microcystic Lymphatic Malformations, Cutaneous Venous Malformations, Angiokeratomas, Disseminated Superficial Actinic Porokeratosis, DSAP, Pitavastatin, Clinical-Stage Biopharmaceutical, FDA Breakthrough Therapy Designation, FDA Fast Track Designation, FDA Orphan Drug Designation, SEC Filing, 10-K, Biotechnology, Pharmaceutical Development, Topical Therapy, mTOR Inhibitor, Clinical Trials, Drug Approval, Intellectual Property, Capital Raise